IP Library Granted Patent US 8,377,656
Granted Patent B2
US 8,377,656 · App. 13/135,022 · Granted Feb 19, 2013

Compositions and methods for detecting

Inventors: Melanie Feola (Cherry Hill, NJ); John Entwistle (Christiansburg, VA); Martin Adelson (Belle Mead, NJ); Eli Mordechai (Robbinsville, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,656
App. No.
13/135,022
Granted
Feb 19, 2013
Kind
B2
Abstract

Disclosed are oligonucleotides useful in methods for determining whether a sample contains Cryptococcus neoformans , a causative agent for human cryptococcosis. These oligonucleotides, which have nucleotide sequences derived from a coding segment of the gene encoding the fungal specific transcription factor gene in Cryptococcus neoformans , are useful as forward and reverse primers for a polymerase chain reaction using nucleic acids from a biological sample as templates, and as probes for detecting any resultant amplicon. Detection of an amplicon indicates the sample contains Cryptococcus neoformans . Real-time PCR and detection using florescence resonance energy transfer is disclosed.

Claims (18)

1. An isolated hybridization probe, wherein said probe has a nucleotide sequence consisting essentially of SEQ ID NO: 5.

2. The isolated hybridization probe of claim 1 , wherein said probe comprises a fluorescent moiety.

3. The isolated hybridization probe of claim 2 , wherein said fluorescent moiety is 6-carboxy-fluorescein.

4. A kit for PCR detection of Cryptococcus neoformans , comprising the isolated hybridization probe of claim 1 , said kit further comprises:

(a) a forward primer that anneals to a Cryptococcus neoformans consensus sequence consisting essentially of nucleotides 1121-1144 of SEQ ID NO: 1;

(b) a reverse primer that anneals to a Cryptococcus neoformans consensus sequence consisting essentially of nucleotides 1512-1533 of SEQ ID NO: 2; and

(c) an instruction for using said forward primer and reverse primer in performing PCR to detect the presence of Cryptococcus neoformans in a sample.

5. The kit of claim 3 , wherein said forward primer has a nucleotide sequence consisting essentially of SEQ ID NO: 3 and said reverse primer has a nucleotide sequence consisting essentially of SEQ ID NO: 4.

6. A kit for PCR detection of Cryptococcus neoformans , comprising the isolated hybridization probe of claim 1 , said kit further comprises:

(a) a forward primer that anneals to a Cryptococcus neoformans consensus sequence consisting essentially of nucleotides 1480-1499 of SEQ ID NO: 1;

(b) a reverse primer that anneals to a Cryptococcus neoformans consensus sequence consisting essentially of nucleotides 1165-1184 of SEQ ID NO: 2; and

(c) an instruction for using said forward primer and reverse primer in performing PCR to detect the presence of Cryptococcus neoformans in a sample.

7. The kit of claim 5 , wherein said forward primer has a nucleotide sequence consisting essentially of SEQ ID NO: 6 and said reverse primer has a nucleotide sequence consisting essentially of SEQ ID NO: 7.

8. A kit for PCR detection of Cryptococcus neoformans , comprising the isolated hybridization probe of claim 1 , said kit further comprises:

(a) a forward primer that anneals to a Cryptococcus neoformans consensus sequence consisting essentially of nucleotides 2105-2124 of SEQ ID NO: 1;

(b) a reverse primer that anneals to a Cryptococcus neoformans consensus sequence consisting essentially of nucleotides 508-527 of SEQ ID NO: 2; and

(c) an instruction for using said forward primer and reverse primer in performing PCR to detect the presence of Cryptococcus neoformans in a sample.

9. The kit of claim 7 , wherein said forward primer has a nucleotide sequence consisting essentially of SEQ ID NO: 8 and said reverse primer has a nucleotide sequence consisting essentially of SEQ ID NO: 9.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
Continuity (2)
Division 12214317 · Jun 18, 2008
Related Publication 20120015362A1 · Jan 19, 2012